- Lead trial lawyer who litigates patent infringement disputes in the life sciences.
- Cases have involved highly-complex biological and chemical inventions, as well as medical devices.
- Leads the firm’s intellectual property practice.
Steve Maslowski works with life sciences companies in major patent litigation involving leading-edge health care treatments. He has been a leader on trial teams for some of the biggest cases in the biotechnology and medical device fields. He also represents clients in matters involving trade secret, tortious interference, trademark and copyright issues.
- Lead counsel for Boston Scientific in patent infringement action against Nevro Corp. in the District of Delaware relating to spinal cord stimulation technology. Following week-long trial, the jury returned a verdict that Nevro directly infringed one Boston Scientific patent, induced its manufacturer to infringe a second patent, and awarded $20 million to Boston Scientific. Currently representing Boston Scientific in related patent and trade secret litigations, as well as parallel petitions for inter partes review before the PTAB, against Nevro.
- Lead counsel for 3M Co., Merck & Co., Inc. and Merck, Sharp & Dohme Corp. in patent infringement suit filed by AptarGroup, Inc. relating to Merck’s Dulera® prescription asthma product. Achieved a complete victory whereby the asserted patents were invalidated in parallel IPRs and the complaint was dismissed with prejudice.
- Represented Bristol-Myers Squibb, Ono Pharmaceutical Co. and Nobel laureate Dr. Tasuko Honjo in patent litigation involving revolutionary immuno-oncology treatment methods. The team’s work contributed to a worldwide settlement that included an initial payment by defendant Merck & Co., Inc. of $625 million and payment of ongoing royalties through 2026.
- Lead counsel for Ethicon-Endo Surgery, a subsidiary of Johnson & Johnson, in an arbitration brought by EndoEvolution alleging trade secret misappropriation, breach of contract, fraud and breach of the implied covenant of good faith and fair dealing in connection with Ethicon’s launch of a new product. At stake were tens of millions of dollars in alleged damages and a potential injunction halting sales of a new product. Obtained complete victory for client on all claims.
- Represented Janssen Biotech Inc. in a patent infringement suit brought by Abbott GMBH & Co. The jury returned a verdict that claims in two patents asserted by Abbott against Janssen’s multi-billion dollar antibody drug product, Stelara®, were invalid. The district court’s judgment was affirmed by the Federal Circuit.
Public Service and Affiliations